The Beauty Health Company - Class A Common Stock (SKIN)
1.4200
+0.0600 (4.41%)
The Beauty Health Co. is a dynamic company specializing in innovative skincare solutions and aesthetic technologies
Focused on enhancing beauty and wellness, the company develops and markets unique products and treatment systems that cater to both professional and consumer markets. By leveraging advanced science and cutting-edge techniques, The Beauty Health Co. aims to address various skincare needs, promoting healthier skin and boosting confidence among its users. The company's commitment to quality and innovation positions it as a leader in the rapidly evolving beauty industry.
Skincare company BeautyHealth (NASDAQSKIN) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales fell by 13.7% year on year to $83.5 million. On the other hand, next quarter’s revenue guidance of $63.5 million was less impressive, coming in 16.6% below analysts’ estimates. Its GAAP loss of $0.08 per share was 30% above analysts’ consensus estimates.
Over the past six months, BeautyHealth’s stock price fell to $1.49. Shareholders have lost 18.1% of their capital, which is disappointing considering the S&P 500 has climbed by 10.4%. This might have investors contemplating their next move.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Inter Parfums (NASDAQIPAR) and the rest of the personal care stocks fared in Q3.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how personal care stocks fared in Q3, starting with BeautyHealth (NASDAQSKIN).
Shares of skincare company BeautyHealth (NASDAQSKIN)
jumped 18.2% in the morning session after the company reported impressive third-quarter earnings that blew past analysts' EBITDA and EBITDA guidance expectations. Notably, the company turned a profit while Wall Street had predicted a loss. Revenue also beat expectations, though sales declined relative to the previous year. The decline in revenue was primarily due to challenges in system sales, particularly in international markets like China. As a result, the company reduced its full-year sales outlook. To overcome some of the challenges impeding growth, the company revamped its commercial leadership team and appointed a new Chief Revenue Officer and Chief Marketing Officer with more relevant expertise. Also, it provided more flexible pricing for markets affected by high interest rates and limited financing availability.
Skincare company BeautyHealth (NASDAQSKIN) announced better-than-expected revenue in Q3 CY2024, but sales fell 19.1% year on year to $78.8 million. On the other hand, the company’s full-year revenue guidance of $327 million at the midpoint came in 4.1% below analysts’ estimates. Its GAAP loss of $0.15 per share was 55.2% below analysts’ consensus estimates.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at personal care stocks, starting with Coty (NYSECOTY).
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the personal care industry, including e.l.f. (NYSEELF) and its peers.
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the personal care industry, including Coty (NYSECOTY) and its peers.
Shares of Lifecore Biomedical, Inc. (NASDAQLFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and board changes. Lifecore Biomedical shares dipped 31.7% to $4.91 on Wednesday.
